Florentina Chirica, MD
Family Medicine · Oregon, OHNPI 1558685206
Payments from drug & device makers
Across 81 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$133
- Pfizer$121
- AstraZeneca$114
- Boehringer Ingelheim$100
- AbbVie$89
- Novo Nordisk$82
- plus $580 from 19 others
What the payments were for
- Food & beverage$1,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 10 | $133 |
| Pfizer | 8 | $121 |
| AstraZeneca | 8 | $114 |
| Boehringer Ingelheim | 7 | $100 |
| AbbVie(2 entities) | 6 | $89 |
| Novo Nordisk | 6 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $69 |
| Amgen | 5 | $66 |
| Lilly USA, LLC | 3 | $54 |
| Novartis | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $37 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $36 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $31 |
| Johnson & Johnson | 2 | $28 |
| Lifescan, Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$1,219 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 164 | $187,469 |
| TrulicityDulaglutide | 157 | $181,430 |
| FarxigaDapagliflozin Propanediol | 134 | $135,447 |
| JanuviaSitagliptin Phosphate | 98 | $103,424 |
| EliquisApixaban | 75 | $78,905 |
| OzempicSemaglutide | 51 | $55,865 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $38,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $19,198 |
| InvokanaCanagliflozin | 19 | $18,763 |
| Spiriva RespimatTiotropium Bromide | 19 | $16,612 |
| Spiriva HandihalerTiotropium Bromide | 20 | $14,320 |
| BrilintaTicagrelor | 16 | $13,075 |
| LivaloPitavastatin Calcium | 12 | $11,239 |
| LinzessLinaclotide | 17 | $11,211 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $10,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $100 | $211,683198 claims |
| Lilly USA, LLCTrulicity | $54 | $181,430157 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $114 | $157,868178 claims |
| MerckJanuvia, Janumet | $133 | $108,093112 claims |
| PfizerEliquis, Paxlovid | $121 | $81,77288 claims |
| Novo NordiskOzempic | $82 | $55,86551 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $13 | $35,70362 claims |
| Johnson & JohnsonInvokana, Xarelto | $28 | $27,00533 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $69 | $11,23912 claims |
| AbbVieLinzess | $89 | $11,21117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Oregon
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.